0001104659-21-113493.txt : 20210907 0001104659-21-113493.hdr.sgml : 20210907 20210907173039 ACCESSION NUMBER: 0001104659-21-113493 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210902 FILED AS OF DATE: 20210907 DATE AS OF CHANGE: 20210907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gad Thomas CENTRAL INDEX KEY: 0001753224 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 211240151 MAIL ADDRESS: STREET 1: C/O Y-MABS THERAPEUTICS, INC. STREET 2: 230 PARK AVENUE, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 4 1 tm2127055-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-09-02 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001753224 Gad Thomas C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169 1 1 0 0 See remarks Common Stock 2021-09-02 4 S 0 50000 33.1783 D 1504927 I By GAD Enterprises LLC Common Stock 2021-09-07 4 M 0 50000 2 A 50000 D Employee Stock Option (right to buy) 2 2021-09-07 4 M 0 50000 0 D 2025-06-10 Common Stock 50000 219000 D This transaction was executed in multiple trades at prices ranging from $33.10 to $33.74. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares. The stock option vested and became exercisable as to 25% of the shares subject to the option on June 10, 2016, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option was 100% vested on June 10, 2019. Chairman, President and Head of Business Development & Strategy /s/ THOMAS GAD 2021-09-07